Evidence map›Paper›PMID 35656701›Full record

ArticlePhysiological reports2022

Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.

Michael P Liesen, Megan L Noonan, Pu Ni, Rafiou Agoro, Julia M Hum, Erica L Clinkenbeard, John G Damrath, Joseph M Wallace, Elizabeth A Swallow, Matthew R Allen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physiological reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Michael P LiesenDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Megan L NoonanDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-1763-1867
Pu NiDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Rafiou AgoroDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Julia M HumDepartment of Physiology, Marian University, Indianapolis, Indiana, USA.
Erica L ClinkenbeardDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
John G DamrathPurdue University Weldon School of Biomedical Engineering, West Lafayette, Indiana, USA.
Joseph M WallaceDepartment of Biomedical Engineering, Indiana University-Purdue University at Indianapolis, Indianapolis, Indiana, USA.
Elizabeth A SwallowDepartment of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Matthew R AllenDepartment of Biomedical Engineering, Indiana University-Purdue University at Indianapolis, Indianapolis, Indiana, USA.
Kenneth E WhiteDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-1244-5261
Indiana University School of MedicineUniversity of Indianapolis · USMarian University - Indiana · USPurdue University West Lafayette · US

Funding

Indiana Medical Scientist/Engineer Training ProgramT32GM077229 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI GASTON, BENJAMIN, HERBERT, BRITTNEY-SHEA · 2008 to 2022
$6.0M
The Effect of Etelcalcetide on Bone-tissue Properties in End Stage Kidney DiseaseF30DK121399 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DAMRATH, JOHN · 2019 to 2023
$256k
Therapeutic potential of HIF-PHDi in the control of bioactive FGF23 in CKD.F31DK122679 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NOONAN, MEGAN · 2019 to 2021
$90k
NIDDK NIH HHS F30DK121399NIDDK NIH HHS F31DK122679NIGMS NIH HHS T32 GM077229
6 · The paper itself

Abstract

Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis-dependent CKD, and for iron deficiency anemia (IDA) in non-dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox-Fgf23/Dmp1-Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre

Indexed as

Fibroblast Growth FactorsIronRenal Insufficiency, ChronicAnimalsCitric AcidDisease Models, AnimalElectrolytesFerric CompoundsFibroblast Growth Factor-23HumansMiceMineralsRNA, MessengerCitric AcidElectrolytesferric citrateFerric CompoundsFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsIronMineralsRNA, MessengerCKDferric citrateGF23ironkidneyklotho

Identifiers

PMID35656701
PMCPMC9163801
OpenAlexW4281681020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.